Related Experiment Video
Updated: Jun 9, 2025
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.1K
Stereotactic Radiosurgery for Intracranial Breast Metastases: A Systematic Review and Meta-Analysis
Neil D Almeida1,2, Cathleen Kuo1,2, Tyler V Schrand3
1Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
Cancers
|October 26, 2024
Summary
Stereotactic radiosurgery (SRS) shows promise for treating breast cancer brain metastases. This approach offers a median survival of 13.1 months and a 53.1% one-year survival rate with manageable side effects.
Area of Science:
- Oncology
- Neurosurgery
- Radiation Oncology
Background:
- Intracranial metastases are a significant challenge in advanced breast cancer.
- Effective treatment options for brain metastases are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of stereotactic radiosurgery (SRS) for breast cancer patients with intracranial metastases.
- To determine survival rates, recurrence patterns, and adverse events associated with SRS in this population.
Main Methods:
- Systematic literature search of PubMed and EMBASE (1990-2024).
- Inclusion of 16 primary research articles with 1228 patients.
- Pooled analysis using the DerSimonian and Laird approach to estimate outcomes.
Main Results:
- Median survival duration of 13.1 ± 3.8 months post-SRS.
- Pooled 1-year overall survival rate of 53.1%.
- 1-year local recurrence rate of 29% and distant recurrence rate of 35%; acute adverse events occurred in 15.5% of patients.
Conclusions:
- Stereotactic radiosurgery is an effective treatment for intracranial breast cancer metastases.
- SRS offers a favorable toxicity profile and promising survival outcomes for patients.
